An interventional study of Low splanchnic blood volume restrictive fluid management strategy and Phlebotomy in Liver Transplantation (LT) and End-stage Liver Disease (ESLD), sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in End Stage Liver Disease with a site in Canada — 1 open to participants now, 2 under way, none of them phase 3. End Stage Liver Disease · Canada.
Among the 12 studies in End Stage Liver Disease with a site in Canada, this one is the only one that started in 2026, is one of 2 with no phase, and was the 12th registered.
155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.
Browse End Stage Liver Disease studies →1 of the 12 studies in End Stage Liver Disease with a site in Canada is open now.
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 1,364 is above the median of 66 across 95 interventional studies indexed under End Stage Liver Disease.
Median enrollment 73 across the 6 interventional studies, 806 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 7 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 4 studies filed under End Stage Liver Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in End Stage Liver Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined with phlebotomy) in improving patients' recovery after surgery. The study compares the low splanchnic blood volume restrictive fluid management strategy to an optimized cardiac-output liberal fluid management strategy (which involves administering more fluids to raise blood pressure with less reliance on medications). Two primary otucomes and other outcomes important to patients will be measured.
This study (REFIL-2) had a vanguard phase (internal pilot) that included 138 patients (NCT05647733). The patients included in the vanguard pilot phase were not compared between groups but only analyzed descriptively using aggregated data. Only feasibility metrics were compared (see NCT05647733). These 138 patients were thus rolled into the REFIL-2 trial and included in the final sample size reported herein.
People with advanced liver disease have poor blood circulation, and too much blood accumulates in the abdomen (a condition known as high intra-abdominal blood volume). However, liver transplantation (LT) is a complex surgery during which the patient can lose a significant amount of blood and blood pressure can fluctuate widely. Therefore, restricting fluids and using medications to raise blood pressure is a strategy that could reduce blood loss and potentially also certain complications after surgery. Furthermore, phlebotomy appears to reduce intra-abdominal blood volume, blood loss, drops in blood pressure, and the need for red blood cell transfusions, potentially improving recovery after surgery. This study therefore aims to determine the best way to manage fluids during a liver transplantation by comparing these two care strategies. Another goal of the study is to measure the cost-effectiveness of the proposed intervention.
Hypothesis: An intraoperative low splanchnic blood volume restrictive fluid management strategy is superior to an optimized cardiac-output liberal fluid management strategy in reducing postoperative severe complications after liver transplantation
Design: Multicenter blinded parallel arm randomized controlled trial
Study population: Adult patients undergoing a liver transplantation for end-stage liver disease (ESLD)
All participants will be followed during their index hospitalization up to post-transplantation Day 30 (whichever comes first), and for 12 months post-transplantation to assess some clinical outcomes, quality of life (QoL), and survival (being alive beyond the index hospitalization).
Participation in this study lasts 12 months.
The results of this study will help determine whether or not to recommend a low splanchnic blood volume restrictive fluid management strategy for people who undergo a liver transplantation.
This study is conducted in two phases: a pilot phase, which demonstrated feasibility across Canada, followed by the current larger-scale phase (REFIL-2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A phlebotomy (a procedure where the patient's blood is drawn, similar to a blood donation, without fluid replacement) at the start of the surgery combined with fluid restriction (use of vasopressor preferentially to treat hemodynamic instability with tolerance to relative hypovolemia defined as a Pulse Pressure Variation (PPV) or Stroke Volume (SVV) up to 18%). Fluids will be administered to compensate for blood loss and/or treat severe hemodynamic instability. Blood collected by phlebotomy will always be transfused back at the beginning of the reperfusion phase, during which fluid management will be based on goal-directed therapy (GDT) using either PPV or SV, as in the control group.
Procedure: Low splanchnic blood volume restrictive fluid management strategy · Procedure: Phlebotomy
Goal-directed therapy (GDT): Patients will receive 250 ml fluid boluses until SV stops increasing by more than 10% or until PPV is below 12%. Fluids will thus be used preferentially to treat hemodynamic instability. Fluids will also be administered to compensate for blood loss and/or treat severe hemodynamic instability.
Procedure: Optimized cardiac output liberal fluid management strategy
Hemodynamic goal-directed restrictive fluid management strategy
Also known as: Restrictive
Blood drawn in a blood donation bag prior to dissection and transfused back after graft reperfusion
Permissive hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
Also known as: Liberal
Number of participants with at least one severe complication up to hospital discharge
Incidence of at least one severe complications defined as a complication of grade ≥ 3 according to the Dindo-Clavien scale (grade 1 to 5)
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants who were transfused at least one unit of red blood cells (RBC) up to hospital discharge
Incidence of participants transfused at least 1 unit of RBC during surgery or after surgery, up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants who were transfused at least one unit of red blood cells (RBC) during surgery
Incidence of at least one RBC transfusion during surgery
Time frame: Intraoperative (from entrance in the operating room to exit of the operating room)
Number of participants who were transfused at least one unit of red blood cells (RBC) during the perioperative period of surgery
Incidence of participants transfused at least 1 unit of RBC during the perioperative period of surgery
Time frame: During surgery (from entrance in the operating to exit of the operating room) and up to 48 hours after surgery (from exit of the operating room to 48 hours after exit of the operating room)
Intraoperative blood loss
Blood loss as estimated by clinicians
Time frame: Intraoperative (from entrance in the operating room to exit of the operating room)
Number of participants who were transfused at least one unit of any labile blood product up to hospital discharge
Incidence of at least one labile blood product transfused from surgery up to hospital discharge
Time frame: From surgery to hospital discharge (from entrance in the operating room to hospital discharge) or 30 days, whichever comes first
7-day quality of recovery
Quality of recovery measured using the 15-item Quality of Recovery (QoR-15) score. Each item is scored on an 11-point numerical rating scale (0-10) for a total between 0 and 150, 0 being the worst possible recovery and 150 being a perfect recovery.
Time frame: One time point: 7 days after surgery (transplantation)
Number of participants with a 7-day graft dysfunction
Incidence of graft dysfunction (as per Olthoff's definition)
Time frame: One time point: 7 days after surgery (transplantation)
Number of participants with a 7-day acute kidney injury (AKI)
Acute kidney injury (AKI) of KDIGO grade 2 or 3
Time frame: Over 7 days after surgery (criteria met at any day from surgery to day 7 after surgery)
Number of participants with at least one postoperative hemorrhagic complication up to hospital discharge
Incidence of at least one postoperative hemorrhagic complication, defined as any bleeding episode associated with a drop of hemoglobin of 20 g/L within 24 hours of bleeding, requiring 2 blood units within 24 hours of bleeding, a surgical hemostasis or an angioembolization.
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants with postoperative acute kidney injury (AKI) up to hospital discharge
Incidence of any postoperative acute kidney injury (AKI) (any grade as per KDIGO criteria) up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants requiring renal replacement therapy (RRT) up to hospital discharge
Incidence of postoperative requirement for renal replacement therapy (RRT) \[hemodialysis or hemofiltration\] up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants with at least one postoperative graft complication up to hospital discharge
Incidence of at least one postoperative graft complication (primary non-function, vascular, biliary) or retransplantation up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants with at least one postoperative infectious complication up to hospital discharge
Incidence of any postoperative infectious complication (other than pneumonia) up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of patients with a postoperative wound dehiscence up to hospital discharge
Incidence of postoperative wound dehiscence or evisceration up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of patients with at least one postoperative pulmonary complication up to hospital discharge
Incidence of any postoperative pulmonary complications (atelectasis, pneumonia, pulmonary oedema) up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants with at least one postoperative thromboembolic complication up to hospital discharge
Incidence of at least one thromboembolic complication (deep vein thrombosis, pulmonary embolism, myocardial infraction, stroke, mesenteric ischemia) up to hospital discharge
Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants with a postoperative ICU readmission up to hospital discharge
Incidence of ICU readmissions after initial discharge (from the planned postoperative ICU or step-down unit admission) to hospital discharge
Time frame: From initial ICU discharge (planned postoperative ICU or step-down unit admission) to hospital discharge or 30 days, whichever comes first
Number of days not in an intensive care unit (ICU) at 30 days after surgery (30-day ICU-free days over 30 days)
Number of days alive and not hospitalized in an ICU. 0 means 30 consecutive days in the ICU or death within 30 days without any day without being in an ICU from surgery to death. 30 means no days hospitalized in an ICU from surgery to the 30-day time point.
Time frame: From surgery to 30 days after surgery
Number of days without organ support at 30 days after surgery (30-day organ support free days)
Number of days alive without renal replacement therapy, mechanical ventilation or vasopressor 30 days after surgery. 0 means 30 consecutive days with any organ support or death within 30 days without any day without organ support from surgery to death. 30 means no days with organ support from surgery to the 30-day time point.
Time frame: From surgery to 30 days after surgery
Hospital length of stay
Length of hospital stay (days)
Time frame: From surgery to hospital discharge (up to 12 months after surgery)
Quality of life score
Quality of life (QoL) score using the 36-item Short Form health survey questionnaire (SF-36). Score ranges from 0 (worst possible health) to 100 (best possible health).
Time frame: Two time points: 6 and 12 months after surgery
Rate of hospital readmissions
Number of postoperative hospital readmissions over 12 months after surgery
Time frame: From hospital discharge after surgery to 12 months after surgery
Rate of 1-year graft complications
Time to any graft complication (vascular or biliary) to 1 year after surgery
Time frame: From surgery to 12 months after surgery
Rate of 1-year graft survival
Time to graft lost (death of retransplantation) up to 1 year after surgery. Censoring will occur if lost to follow-up or 1 year after surgery.
Time frame: From surgery to 12 months after surgery
Rate of 1-year recipient survival
Time to death up to 1 year after surgery. Censoring will occur if lost to follow-up or at 12 months after surgery.
Time frame: From surgery to 12 months after surgery.
Costs of the intervention
Complication-related costs (total and subcomponent costs including complications, ressource utilization and hospital readmissions)
Time frame: Up to 12 months post-transplantation
Plan to share: No — End-of-study knowledge translation (KT) planned
Started Feb 2026 (actual). Primary completion is estimated for Jun 2031, 63 months after the start.
Of 35 non-industry interventional studies with no phase under End Stage Liver Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 72. This study's planned 63 months is above that.
Counting every sponsor, half of 36 studies reached it within 28 months; a quarter within 21 and three quarters within 72.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2030 → Jun 2031 and completion Nov 2031 → Jun 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →